Macrovascular involvement in a child with atypical hemolytic uremic syndrome

Pediatric Nephrology

Volumn 29, Issue 7, 2014, Pages 1273-1277

  Ažukaitis, Karolis ^a   Loirat, Chantal ^b   Malina, Michal ^c   Adomaitiene, Irina ^a   Jankauskiene, Augustina ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Arterial stenoses; Atypical hemolytic uremic syndrome; C3 gain of function mutation; Eculizumab; Fatal stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; COMPLEMENT COMPONENT C3; CREATININE; CYCLOSPORIN A; ECULIZUMAB; HEPARIN; LACIDIPINE; METHYLPREDNISOLONE; MOXONIDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; BODY WEIGHT; CASE REPORT; CHILD; CHILDHOOD DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; GAIN OF FUNCTION MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOYAMOYA DISEASE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; COMPLEMENT ACTIVATION; COMPLICATION; GENETICS; IMMUNOLOGY; MUTATION; STROKE;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; MALE; MUTATION; STROKE;

EID: 84901658759     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2713-3     Document Type: Article

References (28)

1. Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
2. Kavanagh D, Goodship TH (2011) Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematol Am Soc Hematol Educ Program 2011:15-20
3. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45(5):531-6
4. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5(10):1844-59
5. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554-62
6. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13(3):663-75
7. Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28(5):827-30
8. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169-81
9. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Nat Rev Nephrol 8(11):643-57
10. Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V (2013) Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. Am J Kidney Dis S0272-6386(13):01083-4
11. International Pediatric Hypertension Association (2012) Blood pressure limits chart. International Pediatric Hypertension Association. http://www.pediatrichypertension.org/calcs.asp. Accessed 6 Dec 2013
12. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12(12):3337-54
13. Koehl B, Boyer O, Biebuyck-Gougé N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P (2010) Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 25(12):2539-42
14. Sallée M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, Burtey S (2010) Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 25(6):2028-32
15. Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360(12):1226-37
16. Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschênes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V (2010) Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 25(10):3421-5
17. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of Kidney function following treatment with Eculizumab and discontinuation of plazma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with CFH mutation. Am J Kidney Dis 55(4):708-11
18. Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131(1):e331-5
19. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V (2012) A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119(18):4182-91
20. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V (2009) Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114(13):2837-45
21. Lin ZH, Fukuda N, Jin XQ, Yao EH, Ueno T, Endo M, Saito S, Matsumoto K, Mugishima H (2004) Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 44(1):42-7 (Pubitemid 38823485)
22. Széplaki G, Varga L, Füst G, Prohászka Z (2009) Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol Immunol 46(14):2784-93
23. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2011) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59(5):707-10
24. Singla M, John E, Hidalgo G, Grewal D, Macmillan C (2008) Moyamoya vasculopathy in a child after hemolytic uremic syndrome: a possible etiopathogenesis. Neuropediatrics 39(2):128-30
25. Wilson AC, Mitsnefes MM (2009) Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 54(2):345-60
26. Ohanian M, Cable C, Halka K (2011) Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 3:5-12
27. Salem G, Flynn JM, Cataland SR (2013) Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 92(4):557-8
28. Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55(8):758-65